191 related articles for article (PubMed ID: 36635381)
1. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Germing U; Fenaux P; Platzbecker U; Buckstein R; Santini V; Díez-Campelo M; Yucel A; Tang D; Fabre S; Zhang G; Zoffoli R; Ha X; Miteva D; Hughes C; Komrokji RS; Zeidan AM; Garcia-Manero G
Ann Hematol; 2023 Feb; 102(2):311-321. PubMed ID: 36635381
[TBL] [Abstract][Full Text] [Related]
2. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
3. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Oliva EN; Platzbecker U; Garcia-Manero G; Mufti GJ; Santini V; Sekeres MA; Komrokji RS; Shetty JK; Tang D; Guo S; Liao W; Zhang G; Ha X; Ito R; Lord-Bessen J; Backstrom JT; Fenaux P
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011768
[TBL] [Abstract][Full Text] [Related]
6. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
[TBL] [Abstract][Full Text] [Related]
9. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study.
Zhang Z; Hu Q; Tang X; Zhang M; Jia J; Shi H; Ding X; Yang C; Chen M; Han B
Ann Hematol; 2023 Nov; 102(11):3039-3047. PubMed ID: 37682325
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
[TBL] [Abstract][Full Text] [Related]
12. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
13. Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
Tinsley-Vance SM; Davis M; Ajayi O
J Adv Pract Oncol; 2023 Jan; 14(1):82-87. PubMed ID: 36741213
[TBL] [Abstract][Full Text] [Related]
14. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
15. The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.
Delgado J; Voltz C; Stain M; Balkowiec-Iskra E; Mueller B; Wernsperger J; Malinowska I; Gisselbrecht C; Enzmann H; Pignatti F
Hemasphere; 2021 Aug; 5(8):e616. PubMed ID: 34291195
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P
J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480
[TBL] [Abstract][Full Text] [Related]
17. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for myelodysplastic syndromes.
Xu K; Hansen E
J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
[TBL] [Abstract][Full Text] [Related]
19. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Santini V; Almeida A; Giagounidis A; Platzbecker U; Buckstein R; Beach CL; Guo S; Altincatal A; Wu C; Fenaux P
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):136-144.e7. PubMed ID: 29429612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
